)
Edge
Extra Everything: The Story of Chipotle
Chipotle's story from a single restaurant to a nationwide chain, through crisis and turnaround, built on one of the strongest models in the industry.
MaaT Pharma
MaaT Pharma (MAAT) investor relations material
MaaT Pharma AGM 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.AGM 2026 summary16 Jun, 2026
Opening remarks and agenda
The meeting included an introduction, designation of the assembly bureau, a review of 2025 financial performance, voting on resolutions, a Q&A session, and formal closure.
Financial performance review
2025 revenue reached €4.5M, up 38% from 2024, mainly from EAP program compensations in France.
Net loss for 2025 was €31.1M (IFRS) and €28.7M (French standards), reflecting increased clinical and regulatory activities.
Cash and equivalents stood at €24.9M at year-end 2025, with an extension of the cash runway to November 2026.
R&D expenses rose due to ongoing clinical studies (PHOEBUS, CHRONOS), and financial charges increased due to new financing.
Cash flow benefited from capital increases and BEI financing, with a €4.7M increase in cash position.
Board and executive committee updates
Mandates of key board members and administrators were renewed, including the CEO, President, and independent directors.
The board composition and professional backgrounds of candidates were disclosed.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from MaaT Pharma
- Q1 2026 revenue was €0.8M, with cash runway extended to November 2026 amid regulatory challenges.MAAT
Q1 2026 TU26 May 2026 - Pivotal trial success, EMA review, and 38% revenue growth extend cash runway to August 2026.MAATH2 202531 Mar 2026
- MaaT013 shows strong efficacy and safety in refractory aGvHD, with pivotal data due January 2025.MAATKOL Event11 Jan 2026
- Phase 3 data show 62% GI response, 54% survival in aGvHD; EU submission planned for 2025.MAATStudy Result10 Jan 2026
- Clinigen secures exclusive European rights to Xervyteg, targeting approval and launch by mid-2026.MAATStatus Update14 Nov 2025
- Q3 2025 revenue up 45% year-over-year; cash runway secured through February 2026.MAATQ3 2025 TU4 Nov 2025
- 41% revenue growth, €15.1M net loss, and major EU deal extend cash runway to Feb 2026.MAATH1 202517 Sep 2025
- H1 2024 saw revenue growth, deeper R&D-driven loss, and strong progress in late-stage clinical trials.MAATH1 202413 Jun 2025
- Phase 3 ARES trial enrollment completed; Q3 revenues up, cash at €27M, new CFO named.MAATQ3 2024 TU13 Jun 2025
Next MaaT Pharma earnings date
H1 202629 Sep, 2026
MaaT Pharma
Next MaaT Pharma earnings date
H1 202629 Sep, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Explore our global coverage